NorthWest Biotherapeutics Inc (NWBO)

[Bacchus1]

Excellent post. This is truly disruptive technology and, as such, is at great risk of attack by those BP that are financially comfortable with the status quo or those who have bet against the success of this treatment.

Patients with this devastating cancer will benefit hugely from DCVax-L (and DCVax-D) so it is crucial that NWBO do not leave themselves open to any attack.

Validation of the data derived from the P3 trial by clinicians via a peer-reviewed publication (preferably in a leading high-impact factor journal) is essential to prevent the deluge of attacks that will inevitably come after TLD. NWBO is absolutely correct to be following this route although it will of course be Drs Liau, Ashkan et al who will write the manuscript.